Business
At Annual and Special Meeting of Shareholders - Neurochem to officially adopt new name - BELLUS Health - And to provide update on programs including first new natural health product, VIVIMIND(TM)
Neurochem Annual and Special Meeting web cast live LAVAL, QC, April 15 /CNW Telbec/ - At the Annu...
About this update from Bluenergies Ltd.
[{"type":"text","content":"\n\n\n\nNeurochem Annual and Special Meeting web cast live\n\n\nLAVAL, QC, April 15 /CNW Telbec/ - At the Annual and Special meeting of\nNeurochem Inc. (NASDAQ: NRMX; TSX: NRM), shareholders will be asked to\nofficially adopt the Company's new name, BELLUS Health Inc., which it expects\nto start using on April 21, 2008, together with the new stock ticker symbols\n(NASDAQ: BLUS; TSX: BLU). Neurochem will also present the launch activities\nthat are in preparation for VIVIMIND(TM), the first branded natural health\nproduct to be marketed by its new, wholly owned, nutraceutical subsidiary,\nOVOS Natural Health Inc., to protect memory function. Shareholders will also\nlearn that Neurochem has regained full ownership rights and control on\neprodisate (KIACTA(TM)) from Centocor Inc., a wholly owned subsidiairy of\nJohnson and Johnson, for the prevention and treatment of Amyloid A (AA)\namyloidosis.\n\n\n"Fiscal 2007 was a difficult year for Neurochem, but we have risen to the\nchallenge by adopting an expanded corporate strategy to assure revenue\ngeneration in the short-term through the sale of natural health products and\nlong-term development of a rich product pipeline in pharmaceuticals," said\nDr. Francesco Bellini, Neurochem's Chairman, President and Chief Executive\nOfficer. "Our name-change to BELLUS Health will reflect the broader scope of\nour activities, while the creation of our subsidiary, OVOS Natural Health, as\nwell as the imminent launch of VIVIMIND(TM) for memory protection, testify to\nour determination to move ahead quickly. Our proactive strategy is based on\nthe wealth of our past experience and the unique opportunity that the natural\nhealth product market represents to meet the needs of those who could benefit\nfrom this product, while helping to fund our longer-term drug development\nprograms geared to future growth," he stated.\n\n\n"I am particularly pleased to have regained full ownership of KIACTA(TM)\ngiven the promising results from our Phase II/III trial and our intention to\ninitiate another Phase III trial and complete the development of this product\ncandidate," Dr. Bellini concluded.\n\n\nOVOS Natural Health - Launch activities in preparation for VIVIMIND(TM)\n\n\nFifteen years of combined scientific research including clinical trials\nwith over 2,000 individuals in Can...